Evaluation of Safety, Immunogenicity, and Prevention of TB With AERAS-404 and BCG Revaccination in Healthy Adolescents

Phase 2

Completed

• Conditions: Tuberculosis
• Interventions: Drug: Placebo; Biological: Bacillus Calmette-Guérin (BCG); Biological: AERAS-404

• Registration Number: NCT02075203
• Lead Sponsor: Aeras

Brief Summary

Randomized, Placebo Controlled, Partially Blinded Phase II Study to Evaluate Safety, Immunogenicity, and Prevention of Infection with Mycobacterium tuberculosis of AERAS-404 and BCG Revaccination in Healthy Adolescents

Detailed Description

This Phase II, randomized, 3-arm, placebo controlled, partially blinded, clinical trial will be conducted in 990 healthy, HIV-uninfected, QFT-GIT negative, previously BCG vaccinated adolescents. The trial will be conducted at the South African Tuberculosis Vaccine Initiative (SATVI) site in the Western Cape region of South Africa, where epidemiological studies involving thousands of adolescents have been conducted over the last decade to characterize rates of Mtb infection and active TB disease in this age group. Subjects will be enrolled in two sequential cohorts and within each cohort subjects will be randomized in a 1:1:1 ratio to receive either AERAS-404 or saline placebo on Days 0 and 56, or BCG Vaccine SSI on Day 0. The first 90 subjects (30 from each arm) will form the Safety \& Immunogenicity Cohort and will be subject to more intensive collection of safety data, with data reviewed by the Data Monitoring Committee (DMC), principal investigator and local medical monitor. Selected immunogenicity assays, including whole blood intracellular cytokine staining (ICS), will also be performed in this cohort. The remaining 900 subjects will be enrolled into the Correlates Cohort. All 990 subjects in the study will be evaluated for safety and biomarker outcomes, and for prevention of Mtb infection.

The primary Mtb infection endpoint will be QFT-GIT conversion from a negative to positive test, using the manufacturer's recommended threshold of 0.35 IU/mL, at any time-point after Day 84 and through end of follow-up for the primary endpoint. The 84-day 'wash-out' period is stipulated in order to exclude subjects who may have already been Mtb infected, but not yet converted their QFT-GIT test at screening, thus subjects who convert their QFT-GIT at Day 84 will not be included in the analyses of prevention of Mtb infection.

Study Timeline

• Study Start: 2014-02
• Study First Submitted: 2014-02-17
• Study First Submitted QC: 2014-02-27
• Study First Posted: 2014-03-03
• Primary Completion: 2017-08-28
• Study Completion: 2017-10-06
• Results First Submitted: 2019-02-14
• Status Verified: 2019-05
• Results First Submitted QC: 2019-05-27
• Results First Posted: 2019-07-29
• Last Update Submitted: 2019-08-22
• Last Update Posted: 2019-09-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 989

Inclusion Criteria

1. Has completed the written informed consent and assent process
2. Is age ≥ 12 years and ≤ 17 years on Study Day 0
3. Agrees to stay in contact with the study site for the duration of the study, provide updated contact information
4. For female subjects: agrees to avoid pregnancy from 28 days prior to Study Day 0 and for the full duration of the study.
5. Has general good health, confirmed by medical history and physical examination
6. Had BCG vaccination at least 5 years ago documented through medical history or by presence of healed BCG scar
7. Tests QFT-GIT negative at screening, using the manufacturer's recommended threshold of 0.35 IU/mL

Exclusion Criteria

1. Acute illness on Study Day 0
2. Oral temperature ≥37.5°C on Study Day 0
3. Clinically significant (and no more than Grade 1 on the Toxicity Scale) abnormal laboratory values from blood collected within 21 days
4. Evidence of clinically significant (and no more than Grade 1 on the Toxicity Scale) systemic or local disease on urinalysis
5. History or evidence of any clinically significant systemic disease, or any acute or chronic illness that might affect the safety, immunogenicity, or efficacy of study vaccine in the opinion of the investigator
6. History of treatment for active TB disease or latent Mtb infection
7. History or evidence, including chest X-ray, of active TB disease
8. Shared residence with an individual receiving anti-TB treatment, or known incompletely treated culture or smear positive TB
9. History of autoimmune disease or immunosuppression
10. Used immunosuppressive medication within 42 days before Study Day 0
11. Received immunoglobulin or blood products within 42 days before Study Day 0
12. Received any investigational drug therapy or investigational vaccine within 182 days before Study Day 0
13. Received investigational TB vaccine, other than BCG
14. Planned administration/administration of a licensed vaccine in the period starting 28 days before and ending 28 days after each dose of study vaccine
15. History or laboratory evidence of any past or present possible immunodeficiency state not limited to any lab indication of HIV-1 infection
16. History of allergic disease likely to be exacerbated by any component of the study vaccine
17. History of alcohol or drug abuse
18. All female subjects: currently pregnant or lactating/nursing; or positive urine pregnancy test during screening
19. Received a (TST) within 3 months (90 days) prior to Study Day 0.
20. Any current medical, psychiatric, occupational, substance abuse problems problems that in opinion of investigator will make unlikely for the subject to comply with the protocol

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	2 Doses on Study Days 0 and 56
Bacillus Calmette-Guérin (BCG)	Bacillus Calmette-Guérin (BCG)	1 Dose on Study Day 0
AERAS-404 (15 mcgH4/500 nmol IC31)	AERAS-404	2 doses on Study Days 0 and 56

Primary Outcome Measures

Name	Time	Method
Number of Participants Testing Positive for Mtb at Day 84	Study day 84 through 6 months post-conversion	Rates of conversion to Mtb-positive measured by QuantiFERON-TB Gold In-tube (QFT-GIT) assay. The primary evaluation of Mtb infection was QFT-GIT conversion from a negative to positive test, using the manufacturer's recommended threshold of ≥0.35 IU/mL, at any time point after Day 84 and through end of follow-up for the primary endpoint. All participants with primary QFT-GIT conversion were followed for an additional 6 months post-conversion to ascertain the sustained QFT-GIT conversion and QFT-GIT reversion endpoints. Participants with an initial QFT-GIT conversion at Month 6 or 12 were asked to return for a final QFT-GIT evaluation and assessment for TB signs and symptoms at least 24 months after their initial vaccination.; * H4:IC31 compared to placebo; * BCG revaccination compared to placebo
Safety Profile of H4:IC31 and BCG Revaccination in HIV-uninfected, Remotely BCG Vaccinated Adolescents.	Study day 7 thru 6 months after last vaccination	Number of unsolicited and solicited adverse events recorded post vaccination.; Unsolicited adverse events: 28 days post each vaccination; Solicited adverse events: 7 days post each vaccination (with diary cards used for 7 days after each vaccination for Safety and Immunogenicity Cohort only); Solicited and unsolicited injection site reaction adverse events: BCG Group - 84 days post vaccination; H4:IC31/Placebo Groups - 28 days post each vaccination; Serious adverse events, adverse events of special interest, and SUSARs: Entire study period, with a minimum of 6 months following the last dose of study vaccine

Secondary Outcome Measures

Name	Time	Method
Percentage of Participants With Immune Response to Vaccine in HIV-uninfected, Remotely BCG-vaccinated Adolescents: o H4:IC31 o BCG Revaccination	Study day 70	A 13 color intracellular cytokine staining assay (ICS) was performed on peripheral blood mononuclear cells (PBMC) to assess CD4+ T cells that expressed IFN-γ, TNF, IL-2, IL-17, IL-22, CD107a, and/or CD154 alone or in combination in response to stimulation with peptide pools representing the entire amino acid sequence of the TB mycobacterial antigens Ag85B and TB10.4, and BCG antigens. Responders were IFN-gamma and/or IL-2 positive.; An intracellular cytokine assay was performed on whole blood (WB) to measure the frequencies and patterns of CD4+ T cells expressing Th1 and Th17 cytokines following stimulation of whole blood with peptide pools representing the entire amino acid sequence of the TB mycobacterial antigens Ag85B and TB10.4, as well as viable BCG from the vaccine vial. Responders were IFN-gamma, IL-2, TNF, IL-17, and/or IL-22 positive.
Rates of Sustained Conversion to Mtb-positive	6 months after initial conversion	Rates of sustained conversion to Mtb-positive as measured by QFT-GIT assay.; * H4:IC31 compared to placebo; * BCG revaccination compared to placebo

Trial Locations

Locations (2)

Desmond Tutu HIV Foundation (DTHF); 🇿🇦 Nyanga, South Africa

South African Tuberculosis Vaccine Initiative , Project Office, Brewelskloof Hospital , Harlem Street, Worcester; 🇿🇦 Cape Town, Western Cape, South Africa